Key result
Multimodal imaging and monoclonal protein screening unmask stage III AL cardiac amyloidosis years post-ASD repair.
Why the study?
Cardiac amyloidosis frequently mimics other cardiac conditions and is easily overlooked due to diagnostic anchoring bias once a structural cardiac diagnosis has been established.
Case Report (n=1)
No
This case highlights that an established diagnosis of structural heart disease can lead to anchoring bias, and patients with refractory heart failure following structural repair require systematic reassessment with strain echocardiography, monoclonal protein screening, and tissue biopsy to unmask coexisting cardiac amyloidosis.
Answers are grounded in this paper and cite their sources.
Anchoring on prior ASD repair may obscure coexisting AL amyloidosis in refractory HF; this case leaves open systematic strain and biopsy utility.
Background: Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that frequently mimics other cardiac conditions and is easily overlooked once a structural cardiac diagnosis has been established. We report a case of systemic lambda light-chain (AL) amyloidosis unmasked four years after surgical repair of an atrial septal defect (ASD), highlighting the diagnostic anchoring bias that delayed recognition. Case presentation: A 75-year-old woman presented with refractory heart failure four years after surgical repair of an ASD. Her progressively worsening symptoms had been attributed solely to the pre-existing structural heart disease. On readmission, transthoracic echocardiography demonstrated biatrial enlargement, severe mitral and tricuspid regurgitation, biventricular wall thickening with a granular sparkling appearance, and a small pericardial effusion. Three-dimensional speckle-tracking echocardiography revealed profoundly reduced left ventricular global longitudinal strain (GLS, -6.0%) with relative apical sparing, and reduced right ventricular free-wall longitudinal strain (-8.1%). Electrocardiography showed atrial fibrillation, intraventricular conduction delay, and poor precordial R-wave progression. Serum immunofixation electrophoresis detected a lambda-type monoclonal protein, with a markedly elevated free lambda light chain and a decreased kappa/lambda ratio. Abdominal fat pad biopsy showed Congo red-positive amyloid deposits, and electron microscopy revealed rigid, non-branching amyloid fibrils measuring 8-12 nm in diameter, confirming systemic AL amyloidosis. According to the revised Mayo 2012 staging system (NT-proBNP 29,218 pg/mL), she was classified as stage III. The patient declined bone marrow biopsy and clone-directed chemotherapy and was transferred to another hospital for further management. Conclusions: Once a structural cardiac diagnosis is established, clinicians are prone to anchoring bias and may overlook coexisting infiltrative disease. In patients with refractory or progressive heart failure after correction of structural heart disease, systematic reassessment-including strain echocardiography, monoclonal protein screening, and tissue biopsy-should be pursued to unmask CA and enable timely, potentially life-prolonging therapy.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) conducted a case report in Systemic lambda light-chain cardiac amyloidosis with previously repaired atrial septal defect (n=1). Multimodality diagnostic work-up (3D speckle-tracking echocardiography, serum monoclonal protein screening, and abdominal fat pad biopsy) was evaluated on Diagnosis of systemic lambda light-chain (AL) cardiac amyloidosis. Systematic reassessment with 3D speckle-tracking echocardiography, monoclonal protein screening, and fat pad biopsy unmasked stage III AL cardiac amyloidosis 4 years post-ASD repair.
Synapse has enriched 10 related papers. Consider them for comparative context: